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AbsTrACT
Objective to assess the non-inferiority of vonoprazan 
to lansoprazole for secondary prevention of non-steroidal 
anti-inflammatory drug (nSaiD)-induced peptic ulcer 
(PU) and the safety of vonoprazan during extended use.
Design a phase 3, 24-week, multicenter, randomised, 
double-blind (DB), active-controlled study, followed by 
a phase 3, ≥28 week, multicenter, single-blind, parallel-
group extension study (eXt) in outpatients (n=642) 
receiving long-term nSaiD therapy who are at risk of PU 
recurrence. the patients received vonoprazan (10 mg or 
20 mg) or lansoprazole 15 mg once daily. For DB, non-
inferiority of the proportion of patients with recurrent 
PU within 24 weeks was analysed by Farrington and 
Manning test (significance level 2.5%, non-inferiority 
margin 8.3%; primary endpoint), recurrent PU within 
12 weeks, bleeding and time-to-event of PU (secondary 
endpoint) and treatment-emergent adverse events 
(teaes). For eXt, teaes (primary endpoint), recurrent PU 
and safety (secondary) were assessed up to 104 weeks 
for patients in the extension study.
results the non-inferiority of vonoprazan 10 mg and 
20 mg to lansoprazole 15 mg was verified (percentage 
difference –2.2%,95% ci –6.2% to 1.8%, p<0.001; 
–2.1%,95% ci –6.1% to 2.0%, p<0.001, respectively). 
the proportion of patients with endoscopically confirmed 
recurrent PU within 24 weeks was 3.3%, 3.4% and 
5.5%, for vonoprazan 10 mg, 20 mg and lansoprazole 
15 mg, respectively. no significant safety concerns were 
identified.
Conclusion the non-inferiority of vonoprazan (10 
and 20 mg) was verified in patients receiving long-term 
nSaiDs in DB; it was effective and well tolerated in eXt 
for longer than 1 year, with a safety profile similar to 
lansoprazole (15 mg).
Trial registration numbers nct01452750, 
nct01456260; results.
InTrODuCTIOn
Non-steroidal anti-inflammatory drugs (NSAIDs) 
are commonly used to manage pain or inflamma-
tory symptoms in conditions such as rheumatoid 
arthritis and osteoarthritis, but they can cause GI 
mucosal injury.1 In Japan, the prevalence of upper 
GI tract lesions in patients receiving NSAIDs has 
been reported to be as high as 62%, with >17% 
of lesions confirmed as gastric or duodenal (peptic) 
ulcers.2 Despite the presence of lesions, 40% of 
patients may be asymptomatic2; however, GI 
symptoms do not predict the presence of mucosal 
injury.3 4
significance of this study
What is already known on this subject?
 ► Non-steroidal anti-inflammatory drugs (NSAIDs) 
are commonly used as first-line analgesic agents, 
despite the risk of causing severe GI adverse 
events, such as GI bleeding. The prevalence of 
upper GI tract lesions in patients receiving NSAIDs 
is very high and >17% of lesions are confirmed as 
gastric or duodenal (peptic) ulcers.
 ► Proton pump inhibitors (PPIs) are recommended 
as a prevention of NSAID-related upper GI adverse 
events. However, as PPIs are not completely 
effective, better drugs for the prevention of these 
events are eagerly anticipated.
 ► Vonoprazan competes with potassium to inhibit 
H+, K+-ATPase; it does not require acid-induced 
activation, therefore vonoprazan demonstrated 
more potent and more sustained suppression of 
gastric acid secretion than lansoprazole in the 
preclinical studies.
What are the new findings?
 ► Vonoprazan (10 mg and 20 mg) was effective and 
well tolerated for prevention of NSAID-related 
peptic ulcer recurrence, and its efficacy level 
was equivalent to that of lansoprazole in at-risk 
patients.
 ► The safety profile of vonoprazan (10 mg and 
20 mg) during long-term use was similar to that 
of lansoprazole 15 mg, and no new safety issue 
was identified.
 ► Daily vonoprazan dose of 10 mg can be 
considered as the recommended clinical dose 
for prevention of NSAID-related peptic ulcer 
recurrence in at-risk patients.
How might it impact on clinical practice in the 
foreseeable future?
 ► Vonoprazan has the possibility to become a new 
treatment option for the prevention of NSAID-
related GI adverse events in high-risk patients.
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Current guidelines recommend that the first step for patients 
with NSAID-induced ulcers is discontinuation of NSAIDs5; 
however, such a strategy is not always feasible as arthritic pain 
may recur and negatively impact quality of life.6 Continuing 
NSAID therapy while preventing peptic ulcers is thus consid-
ered clinically important for the management of musculoskeletal 
pain.7
The efficacy of proton pump inhibitors (PPIs), double-doses 
of histamine-2 receptor antagonists (H2RAs) and prostaglandin 
analogues (misoprostol) for primary and secondary prevention 
of NSAID-induced ulcers has been demonstrated in some studies 
and PPIs are currently widely used as first-line drugs.7 8 In Japan, 
lansoprazole at a dose of 15 mg was approved for the first time 
in 2010 for the prevention of recurrence of peptic ulcer during 
NSAID administration. However, as it has been reported that 
up to 13% of patients treated with lansoprazole still experience 
ulcer recurrence,9 alternative secondary prevention treatment 
options continue to be sought.10 An earlier study has reported 
the efficacy of cyclo-oxygenase-2 (COX-2) inhibitors (celecoxib) 
and PPIs (esomeprazole) for patients at very high risk for recur-
rent ulcer bleeding.11
Vonoprazan, a potassium-competitive acid blocker (P-CAB), 
inhibits H+, K+-ATPase at the final stage of the acid secretory 
pathway in gastric parietal cells.10 12 Unlike PPIs, vonoprazan 
competes with potassium to inhibit the H+, K+-ATPase and 
also does not require acid-induced activation.13 14 While PPIs 
typically require approximately 3–5 days to exert a maximal 
effect on gastric acid secretion,15 P-CABs produce strong and 
long-lasting inhibitory activity from the first dose.16 Results 
from a drug–drug interaction study showed that the pharma-
cokinetics of vonoprazan and NSAIDs (loxoprofen sodium, 
diclofenac sodium, meloxicam) were not affected during 
concomitant administration of repeated doses.17 The similar 
efficacy of vonoprazan and lansoprazole for the healing 
of gastric and duodenal ulcers has been demonstrated in a 
randomised clinical trial in patients with gastric and duodenal 
ulcers.18
The aim of the current studies was to evaluate the non-infe-
riority of vonoprazan to lansoprazole for secondary prevention 
of peptic ulcers in patients requiring NSAID therapy for pain 
management and to evaluate the safety and tolerability of vono-
prazan during extended use.
MATerIAls AnD MeTHODs
Trial design
Double-blind, multicenter, randomised, parallel-group, phase 
3 study conducted in Japan to evaluate the non-inferiority 
of vonoprazan to lansoprazole in preventing occurrence of 
secondary ulcers in patients with a history of endoscopically 
confirmed gastric or duodenal ulcer (peptic ulcer) who require 
long-term NSAID therapy. Patients were randomised to receive 
study drug for a period of 24 weeks (figure 1A; figure 1 in the 
online supplementary file 1).
Endoscopic evaluations were conducted at weeks 12 and 24. 
Adverse events (AEs), physical examinations, medication compli-
ance, vital signs and tests (clinical laboratory, pregnancy, serum 
gastrin (reference value of 37–172 pg/mL) and pepsinogen I and 
II by RIA/PEG method) were performed at weeks 4, 8, 12, 16, 
20 and 24.
Single-blind extension study
Subjects who completed the non-inferiority study were 
eligible for enrolment in the phase 3, multicenter, single-blind, 
parallel-group extension study to evaluate safety and ulcer recur-
rence during longer-term exposure. Patients were enrolled into 
the extension study on the day following the final visit of the 
preceding study and were required to complete a minimum of 
28 weeks of follow-up up to a maximum of 80 weeks follow-up 
(figure 1B; figure 1 in the online supplementary file 1).
Using times from starting the double-blind study, endoscopy 
was performed at weeks 52, 76 and 104, and laboratory tests 
(clinical laboratory, pregnancy, serum gastrin and pepsinogen I 
and II) were performed at weeks 36, 52, 64, 76, 88 and 104. 
AEs, vital signs and physical examinations were performed every 
4 weeks starting from week 28 to the end of participation in the 
study.
Participants
Subjects were enrolled in the double-blind study if they met the 
following criteria: male or female outpatients aged ≥20 years 
with a history of peptic ulcer (documented endoscopically 
confirmed ulcer and/or endoscopically confirmed ulcer scars 
within 9 days before randomisation) who required continuous 
long-term therapy with NSAIDs during the treatment period 
for pain control related to a chronic disease (eg, rheumatoid 
arthritis, osteoarthritis). Adequate contraception for women of 
childbearing potential was required from the time of signing 
informed consent up to 4 weeks after the final dose. The eligi-
bility of history of active ulcer or the presence of ulcer scar 
(defined as regenerative mucosa, fold convergence, wall defor-
mation) at baseline endoscopy was determined by the Central 
Evaluation Committee consisting of two board-certified endos-
copists (YM and KA). The Committee made an atlas of endo-
scopic images and held three educational investigator meetings 
for the standardisation.
Subjects were excluded if they had: endoscopically confirmed 
active ulcers or bleeding in the stomach or duodenum; intestinal 
or GI bleeding of unknown aetiology; scheduled operation or 
history of surgery affecting gastric acid secretion (eg, previous 
resection of the upper GI tract, vagotomy); history of gastric 
acid hypersecretion disorders (eg, Zollinger-Ellison syndrome); 
history of aspirin-induced asthma; history of hypersensitivity 
to vonoprazan, NSAIDs, or PPIs; illicit drug or alcohol abuse 
within the previous year; pregnancy, lactation, or intention 
to become pregnant or donate ova; any serious neurological, 
cardiovascular, pulmonary, hepatic, renal, metabolic, GI, urolog-
ical, endocrinological or haematological disorders; history of 
malignancy within 5 years prior to screening; abnormal labo-
ratory test values on the day of screening (creatinine >2 mg/
dL, aspartate aminotransferase (AST) or alanine aminotrans-
ferase (ALT) >2.5×upper limit of normal (ULN), total bili-
rubin >2.0×ULN). The purpose of this trial was to evaluate the 
efficacy of secondary prevention, not healing, and thus active 
ulcers and ulcer bleeding were not included. Further, the use of 
NSAID in patients with active ulcer is contraindicated and hence 
prohibited in Japan. Therefore, ethical committees do not allow 
the enrolment of such patients.
Interventions
During the double-blind and extension studies, all patients 
received a combination of one vonoprazan tablet (10 mg or 
20 mg) or one placebo tablet and one lansoprazole 15 mg 
capsule or one placebo capsule once daily orally after breakfast. 
The 15 mg dose of lansoprazole was selected because that is the 
only dose approved for the prevention of NSAID-induced ulcer 
in Japan. Vonoprazan doses of 10 mg and 20 mg were selected 
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based on results from a dose-ranging study conducted in Japa-
nese patients with erosive oesophagitis where the non-inferiority 
of vonoprazan (at doses of 5, 10, 20 and 40 mg) to lansoprazole 
30 mg was demonstrated.19 Furthermore, in previous clinical 
studies using PPIs, the investigated doses for prevention of ulcer 
recurrence were equivalent to or one-half of the therapeutic 
dose.20
The administration of an NSAID had to have started before 
the initiation of the study treatment and followed the dosage 
and administration specified in the package insert of the NSAID. 
Figure 1 Patient disposition in the double-blind (A) and extension (B) studies.(A) Phase 3, multicenter, randomised, double-blind, parallel-group, 
non-inferiority study conducted to evaluate the non-inferiority of vonoprazan to lansoprazole in preventing occurrence of secondary ulcers in patients 
with a history of endoscopically confirmed gastric or duodenal ulcer (peptic ulcer) who require long-term NSAID therapy. (B) Phase 3, multicenter, 
single-blind, parallel-group extension study to evaluate the safety and ulcer recurrence during long-term drug exposure; subjects who completed the 
non-inferiority study were eligible for enrolment. One patient did not receive study medication. One patient was excluded due to protocol violations.
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Patients on selective COX-2 inhibitors were also enrolled. The 
replacement of the NSAID with another NSAID and the change 
of its dosage were restricted. Aspirin at a dose of 1000 mg or 
higher daily was considered as an NSAID.
randomisation and blinding
An assignment manager (designated by the sponsor) generated a 
randomisation table. Patients were assigned to receive the next 
available study drug number allocated to each study site.
Bias was minimised by employing double-dummy blinding. 
The appearance of the vonoprazan 10 mg, 20 mg and placebo 
tablets and the appearance of the lansoprazole 15 mg and placebo 
capsules were identical. Emergency key codes were stored by the 
Emergency Key Code Management Centre until the key code 
was broken in the event of an emergency or when the database 
was locked for all subjects.
Outcomes
The primary endpoint of the double-blind study was the propor-
tion of patients with recurrent peptic ulcer during 24 weeks of 
treatment. Ulcer was defined as a mucosal defect with white coat 
of 3 mm or larger, measured using endoscopic forceps. Secondary 
endpoints were the proportions of patients with recurrent peptic 
ulcer up to 12 weeks, the proportion of patients with endoscop-
ically proven bleeding in the stomach or duodenum evaluated 
according to the cases classified as I or II by modified Forrest 
classification21 at week 12 and at week 24 and the time to event 
of peptic ulcer. Endoscopic findings (for ulcer scarring and 
recurrence) were investigated independently and blindly by the 
Central Evaluation Committee.
Safety was assessed on the basis of treatment-emergent AEs 
(TEAEs), laboratory test results, ECG, vital signs, serum gastrin 
and pepsinogen I or II levels. Serum gastrin (see table 1A in 
the online supplementary file 2) and pepsinogen I and II levels 
(see tables 1B and 1C in the online supplementary file 2) were 
measured, as it has been shown (phase 2 dose-ranging study) that 
they are significantly increased in patients with erosive oesopha-
gitis receiving vonoprazan ≥10 mg.19 Before the study initiation, 
the special interest AEs (SIAEs) were liver function test abnor-
malities, defined as AST or ALT>3× ULN or two consecutive 
measurements of total bilirubin >2 x ULN.
The primary endpoint of the extension study was the inci-
dence of TEAEs. Safety was assessed in the same manner as in 
the double-blind study. The secondary efficacy endpoint was the 
proportion of patients with recurrent peptic ulcer. Secondary 
endpoints were the proportion of patients with bleeding in the 
stomach or duodenum and time to event of peptic ulcer.
statistical analysis
Analyses were performed on combined data obtained from the 
double-blind and extension studies. All efficacy analyses were 
based on the full analysis set (FAS), defined as all randomised 
patients who received at least one dose of study medica-
tion. Demographics and other baseline characteristics were 
summarised using descriptive statistics (number of subjects, 
means and SD) for continuous variables and frequencies for cate-
gorical variables.
The primary objectives of the study were to demonstrate 
the non-inferiority of vonoprazan compared with lansoprazole 
and to support the new drug application of vonoprazan for the 
prevention of peptic ulcer recurrence during NSAID therapy in 
Japan. The non-inferiority of vonoprazan 10 mg and 20 mg to 
lansoprazole 15 mg was tested using the Farrington and Manning 
test.22 A planned sample size of 210 patients per treatment arm 
(630 patients in total) was based on historical recurrence rates 
in Japanese patients.10 This planned sample size was estimated 
to provide 154 subjects per treatment group after allowing for 
dropouts and at least 90% power to detect non-inferiority of 
vonoprazan to lansoprazole with a one-sided significance level of 
2.5% and a non-inferiority margin of 8.3%. The margin selected 
was half the value of the treatment difference observed between 
lansoprazole 15 mg and gefarnate reported in a previous phase 3 
study.9 A closed testing procedure23 was used for multiplicity 
adjustment in the tests.
Recurrence rates of gastric or duodenal ulcer and the asso-
ciated two-sided 95% CIs were calculated for each visit by 
treatment group. Recurrence rate differences between each 
vonoprazan treatment group and the lansoprazole 15 mg group 
were calculated for each visit using the combined data from the 
double-blind and extension studies. The cumulative incidences 
of peptic ulcer recurrence were calculated by the Kaplan-Meier 
method.
For the combined double-blind and extension studies, safety 
was assessed using the safety analysis set (defined as all patients 
who received study medication) and the frequency distribution 
of TEAEs was determined for each treatment group. Descrip-
tive statistics were used to summarise continuous variables for 
observed values and changes from baseline at each visit. For cate-
gorical variables, shift tables indicated the number of patients in 
each category at baseline and each post-baseline visit.
Analyses were performed using SAS software (V.9.2; SAS Insti-
tute, Cary, North Carolina, USA).
ethics approval
The studies were approved by the Institutional Review Board at 
each study site and were conducted in accordance with the Inter-
national Conference on Harmonisation Guidelines for Good 
Clinical Practice, the principles of the World Medical Association 
Declaration of Helsinki and Japanese regulatory requirements. 
Patients provided written informed consent to participate. The 
studies were registered at  ClinicalTrials. gov: NCT01452750 
(double-blind study) and NCT01456260 (extension study).
role of the funding source
The studies (NCT01452750 and NCT01456260) were funded in 
full by Takeda Pharmaceutical Company, Ltd. Takeda Pharmaceu-
tical Company Ltd. contributed to the study design, research, inter-
pretation of data, writing, reviewing and approving the publication.
resulTs
subject disposition
The double-blind study was conducted at 129 of 137 contracted 
sites in Japan from October 2011 to June 2013. Of the 1208 
patients who provided informed consent, 642 were randomly 
assigned on a 1:1:1 basis to receive vonoprazan 10 mg, vono-
prazan 20 mg or lansoprazole 15 mg; 641 patients were treated 
with the study drug and one patient was excluded because of a 
protocol violation; therefore, 640 patients comprised the FAS 
and safety analysis set (figure 1A). In all, 588 patients completed 
24 weeks of treatment in the double-blind study. Main reasons 
for discontinuing study drug were AEs (n=31), voluntary with-
drawal (n=10) and discontinuation of NSAID (n=5).
The extension study with planned enrolments of 140 patients 
was conducted from April 2012 to December 2013 and involved 
117 of the original sites. Of the patients who completed the first 
study, 406 patients gave consent to proceed to the extension phase 
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and 357 completed at least 28 weeks of treatment (figure 1B). 
Main reasons for failing to complete study treatment in the 
remaining 49 patients were AEs (n=21), voluntary withdrawal 
(n=14) or discontinuation of NSAID (n=8).
Combined participation in the two studies ranged from 52 to 
104 weeks.
baseline demographics
Treatment groups were well matched at baseline for demo-
graphic and other clinical characteristics (table 1). The mean 
serum gastrin concentration at baseline was slightly higher 
in the vonoprazan 20 mg group, but no clinically meaningful 
differences were noted among treatment groups for other 
parameters.
efficacy
The proportion of patients in the FAS population with endo-
scopically confirmed recurrent peptic ulcers within 24 weeks 
was lower for the vonoprazan 10 mg (3.3%) and 20 mg (3.4%) 
groups compared with the lansoprazole 15 mg group (5.5%) 
(figure 2). The non-inferiority of vonoprazan 10 mg and 20 mg 
to lansoprazole was verified because the percentage difference 
between treatment groups was <8.3% (percentage difference 
–2.2%, 95% CI –6.2% to 1.8%, p<0.001; –2.1%, 95% CI 
–6.1% to 2.0%, p<0.001, respectively).
Peptic ulcer recurred in the pyloric antrum (7), upper gastric 
body (3) and middle gastric body (1) for the lansoprazole group; 
pyloric antrum (4), upper gastric body (1), lower gastric body 
(1) and angular region (1) for the vonoprazan 10 mg group and 
pyloric antrum (4), upper gastric body (1), angular region (1) 
and duodenal bulb (1) for the vonoprazan 20 mg group. At each 
evaluation time point from weeks 12 to 104, the proportion of 
patients with recurrent peptic ulcer was lower with vonoprazan 
10 mg and 20 mg compared with lansoprazole 15 mg, but the 
differences between the treatment groups were not statistically 
significant (table 2). Similarly, the proportion of patients with 
bleeding in the stomach or duodenum was consistently lower 
with vonoprazan 10 mg and 20 mg compared with lansoprazole 
15 mg at all evaluation time points from weeks 12 to 104, and 
once again the differences versus lansoprazole were not statisti-
cally significant (table 2).
The Kaplan-Meier cumulative incidence rates of peptic ulcer 
recurrence (figure 3A) and bleeding occurrence (figure 3B) were 
similar or lower in both vonoprazan groups compared with the 
lansoprazole 15 mg group.
safety and tolerability
Across both studies, the incidence of any TEAE was similar 
among treatment groups without any apparent dose-depen-
dent increase between vonoprazan 10 mg and 20 mg (table 3). 
AEs for which a relationship with study medication could not 
be ruled out occurred in <20% of patients in each treatment 
group. There were more AEs leading to study discontinuation 
reported in the vonoprazan 20 mg group than the other groups. 
The vonoprazan 20 mg group also recorded the highest number 
of serious AEs (36 events in 30 patients), but only two of these 
events (subcutaneous abscess and muscular weakness) were 
considered to be drug related.
The most common TEAE in all treatment groups was naso-
pharyngitis (~30% of patients), followed by fall and contusion 
(table 3). Most TEAEs were mild in intensity. Two drug-related 
serious AEs (aortic valve incompetence and putamen haem-
orrhage) were recorded in the vonoprazan 10 mg group, two 
drug-related serious AEs (subcutaneous abscess and muscular 
weakness) were recorded in the vonoprazan 20 mg group and 
one death (due to atherosclerosis) considered unrelated to 
treatment, occurred in the vonoprazan 20 mg group during the 
double-blind study.
The number and incidence of SIAEs were low and similar 
between treatment groups (table 3). Drug-related SIAEs included 
abnormal hepatic function (n=1) in the lansoprazole 15 mg 
group and drug-induced liver injury (n=1) and putamen haem-
orrhage (n=1) in the vonoprazan 10 mg group.
No clinically significant changes were observed pretreatment 
and post-treatment in any group for vital signs or for haema-
tology tests, serum chemistry and urinalysis. Clinically signifi-
cant ECG changes were reported in the vonoprazan 10 mg group 
(week 24, n=1; week 52, n=1) and lansoprazole 15 mg group 
(week 52, n=1; week 64, n=1).
Serum gastrin levels increased from baseline through to week 
52 in all treatment groups (figure 4; see table 1A in the online 
supplementary file 2). Serum gastrin levels were consistently 
Table 1 Demographic and baseline characteristics
Characteristics lansoprazole 15 mg (n=212) Vonoprazan 10 mg (n=218) Vonoprazan 20 mg (n=212)
  Age, years, mean (SD) 65.2 (10.43) 65.0 (11.60) 64.9 (11.37)
Gender, n (%)
  Male 75 (35.4) 89 (40.8) 92 (43.4)
  Female 137 (64.6) 129 (59.2) 120 (56.6)
  BMI, kg/m2, mean (SD) 24.1 (4.40) 24.6 (4.13) 24.0 (4.02)
Underlying chronic disease, n (%)
  Rheumatoid arthritis 67 (31.6) 66 (30.3) 67 (31.6)
  Osteoarthritis 75 (35.4) 92 (42.2) 65 (30.7)
  Other 128 (60.4) 131 (60.1) 130 (61.3)
NSAID used for long-term therapy, n (%)
Selective COX-2 inhibitor 51 (24.1) 65 (29.8) 71 (33.5)
  Other 161 (75.9) 153 (70.2) 141 (66.5)
  Serum gastrin at screening, pg/mL, 
mean (SD)
270.5 (340.04) 309.2 (377.76) 320.1 (609.75)
Serum gastrin at screening by RIA/PEG method. Reference value: 37–172 pg/mL.
BMI, body mass index; COX, cyclo-oxygenase; NSAID, non-steroidal anti-inflammatory drug.
Other NSAIDs used for long-term therapy included: loxoprofen sodium hydrate, meloxicam, diclofenac sodium, etc.
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higher with vonoprazan than with lansoprazole, and the degree 
of increase with vonoprazan was dose dependent.
DIsCussIOn
This is the first report to assess the efficacy and safety of vono-
prazan for prevention of peptic ulcer recurrence in patients 
receiving long-term NSAID therapy. The results from these 
two phase 3 studies support the effectiveness of vonoprazan in 
preventing secondary ulcer recurrence at doses of 10 mg and 
20 mg in Japanese patients receiving NSAIDs. Both doses of 
vonoprazan were non-inferior to lansoprazole 15 mg and the 
ulcer-preventive effects were maintained for longer than 1 year 
Figure 2 Peptic ulcer recurrence at week 24. The proportion of patients in the full analysis set population with endoscopically confirmed recurrent 
peptic ulcers within 24 weeks was lower for the vonoprazan 10 mg and 20 mg groups compared with the lansoprazole 15 mg group. *Non-inferiority 
p<0.001 versus lansoprazole 15 mg. Error bars indicate 95% CIs.
Table 2 Proportion of patients with recurrent peptic ulcer or bleeding (full analysis set)
Visit Treatment
recurrent peptic ulcer bleeding
estimate % (n/n) Difference % 95% CI estimate % (n/n) Difference % 95% CI
  Week 12
  
  
Lansoprazole 15 mg 5.0 (10/199) 2.0 (4/200)
Vonoprazan 10 mg 2.9 (6/209) –2.2 −5.941 to 1.632 1.0 (2/210) –1.0 −3.391 to1.296
Vonoprazan 20 mg 3.0 (6/203) –2.1 −5.896 to 1.757 1.0 (2/199) –1.0 −3.379 to1.389
  Week 24
  
  
Lansoprazole 15 mg 5.5 (11/199) 2.0 (4/200)
Vonoprazan 10 mg 3.3 (7/209) –2.2 −6.182 to 1.826 1.4 (3/210) –0.6 −3.090 to 1.94]
Vonoprazan 20 mg 3.4 (7/203) –2.1 −6.127 to 1.968 1.0 (2/199) –1.0 −3.379 to 1.38]
  Week 52
  
  
Lansoprazole 15 mg 7.0 (14/199) 2.0 (4/200)
Vonoprazan 10 mg 3.8 (8/209) –3.2 −7.611 to 1.196 1.4 (3/210) –0.6 −3.090 to 1.947
Vonoprazan 20 mg 5.4 (11/203) –1.6 −6.341 to 3.108 1.5 (3/199) –0.5 −3.068 to 2.083
  Week 76
  
  
Lansoprazole 15 mg 7.5 (15/199) 2.0 (4/200)
Vonoprazan 10 mg 3.8 (8/209) –3.7 −8.207 to 0.787 1.4 (3/210) –0.6 −3.090 to 1.947
Vonoprazan 20 mg 5.9 (12/203) –1.6 −6.523 to 3.271 1.5 (3/199) −0.5 −3.068 to 2.083
  Week 104
  
  
Lansoprazole 15 mg 7.5 (15/199) 2.0 (4/200)
Vonoprazan 10 mg 3.8 (8/209) –3.7 8.207 to 0.787 1.4 (3/210) –0.6 −3.090 to 1.947
Vonoprazan 20 mg 5.9 (12/203) –1.6 6.523 to 3.271 1.5 (3/199) –0.5 −3.068 to 2.083
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(as shown in table 2). The ulcer-preventive effects of lansopra-
zole (active control) were consistent with previously published 
studies.9 24 The studies also support the safety of long-term 
use of vonoprazan, which was similar to that of lansoprazole 
15 mg. Importantly, no unexpected safety concerns were iden-
tified during the longer than 1 year exposure to vonoprazan.
Japanese guidelines recommend concomitant use of PPIs or 
prostaglandin analogues with NSAIDs for the prevention of 
NSAID-induced ulcers.5 Few studies have directly compared 
these agents; however, a meta-analysis revealed that while 
PPIs, double-dose H2RAs and prostaglandin analogues are 
effective in secondary ulcer prevention, these agents may not 
be completely effective.25 Therefore, PPIs with higher efficacy 
and fewer AEs may be considered the best choice for preven-
tion of secondary ulcers.25 The results of the current studies 
are consistent with those of previous studies that investigated 
the effectiveness of PPIs in secondary ulcer prevention in 
Japanese patients.9 26 27 Furthermore, they demonstrate that 
vonoprazan is as effective as lansoprazole. The proportion 
of patients with recurrent ulcer and bleeding was lower with 
vonoprazan compared with lansoprazole, though the differ-
ences were not statistically significant. Therefore, vonoprazan 
has the potential to be a clinically useful alternative to PPIs, 
especially for patients with high risk factors.
As not all patients receiving NSAIDs develop peptic ulcers 
during treatment, the study specifically enrolled subjects with 
risk factors, namely, a history of endoscopically confirmed 
peptic ulcer and the requirement for continuous long-term 
NSAID therapy (including a selective COX-2 inhibitor) for pain 
management. The numerically greater preventive effect of vono-
prazan 10 mg and 20 mg compared with lansoprazole 15 mg on 
ulcer recurrence was evident within 12 weeks of treatment and 
Figure 3 Kaplan-Meier cumulative incidence of peptic ulcer recurrence (A) and bleeding (B)The cumulative incidence rates of peptic ulcer recurrence 
and bleeding occurrence were similar or lower in both vonoprazan groups compared with the lansoprazole group.
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was maintained up to 2 years. Interestingly, the ulcer recurrence 
rate within 24 weeks observed with lansoprazole 15 mg in the 
present study (5.5%) was similar to that reported in a phase 
3 study of lansoprazole 15 mg conducted in a similar popula-
tion also receiving long-term NSAID therapy (5.9%).10 Despite 
the small number of patients with bleeding in the stomach and 
duodenum throughout the course of the study, the proportion of 
patients with bleeding was consistently lower with vonoprazan 
10 mg or 20 mg compared with lansoprazole 15 mg from week 
12 through to week 104.
Vonoprazan was well tolerated with no apparent dose-depen-
dent increase in the incidence of TEAEs. The safety profiles of 
the 10 mg and 20 mg doses were similar to that of lansoprazole 
15 mg over 104 weeks’ treatment. Although a greater number 
of patients in the vonoprazan 20 mg group discontinued treat-
ment due to TEAEs, there was no clear pattern either by event or 
system organ class to account for this observation. Seven patients 
treated with vonoprazan 20 mg discontinued treatment because 
of musculoskeletal disorders (compared with one patient treated 
with lansoprazole 15 mg and no patients treated with vonoprazan 
10 mg), but the events were likely related to the underlying condi-
tion. Nevertheless, this finding may be worthy of further investi-
gation. The death in the vonoprazan 20 mg group was attributed 
to atherosclerosis and was considered unrelated to treatment.
Mean serum gastrin concentrations were consistently higher from 
week 4 onwards in both vonoprazan treatment groups compared 
with the lansoprazole treatment group, and the increases were 
dose dependent. However, the changes were not considered clin-
ically meaningful and no patients withdrew from either treatment 
group. Levels tended to plateau after week 4 and then increased 
gradually throughout the remainder of the study. The increase in 
serum gastrin concentration is believed to be a consequence of the 
potent gastric acid antisecretory effect of vonoprazan.
The strengths of the study include the use of lansoprazole as an 
active comparator versus two doses of vonoprazan, the double-
blind study design with the large sample size and the parallel-group 
extension study design with long-term exposure. Additionally, 
the double-blind study included a conservative and reliable active 
control rate of 5.5%, long duration of follow-up and robust analyt-
ical and statistical methods. However, the variable duration of drug 
exposure in the extension study may limit our conclusions.
In conclusion, vonoprazan 10 mg and 20 mg were effective and 
well tolerated for prevention of peptic ulcer recurrence during 
NSAID therapy in at-risk Japanese patients and the preventive 
effect was maintained with long-term use. The safety profile of 
vonoprazan 10 mg and 20 mg during long-term use was similar 
to that of lansoprazole 15 mg and no new safety issues were 
identified. The lower dose of 10 mg has been approved in Japan 
Table 3 Summary of TEAE occurring in ≥5% of patients across the non-inferiority and extension studies (safety analysis set)
event
lansoprazole 15 mg 
(n=210) Vonoprazan 10 mg (n=218) Vonoprazan 20 mg (n=212)
statistical testevents, n Patients, n (%) events, n Patients, n (%) events, n Patients, n (%)
Summary of AEs Χ2 test
  Any AE 634 185
(88.1)
758 184
(84.4)
731 175
(82.5)
p=0.2673
  Drug-related AE 44 40
(19.0)
52 38
(17.4)
51 37
(17.5)
p=0.8839
  Leading to study discontinuation 17 16
(7.6)
9 9
(4.1)
32 27
(12.7)
p=0.0046
  Any serious AE* 20 18
(8.6)
22 18
(8.3)
36 30
(14.2)
p=0.0796
  Serious drug-related AE† 0 0
(0)
2 2
(0.9)
2 2
(0.9)
p=0.3740
  Special interest AE‡ 2 2
(1.0)
5 5
(2.3)
4 3
(1.4)
p=0.5232
  Drug-related special interest AE 1 1
(0.5)
2 2
(0.9)
0 0
(0)
p=0.3792
TEAEs reported in ≥5% of patients in any treatment group by preferred term, n (%)
  Nasopharyngitis 61 (29.0) 70 (32.1) 59 (27.8)
  Fall 18 (8.6) 22 (10.1) 18 (8.5)
  Contusion 20 (9.5) 17 (7.8) 14 (6.6)
  Diarrhoea 14 (6.7) 11 (5.0) 15 (7.1)
  Upper respiratory tract inflammation 7 (3.3) 12 (5.5) 14 (6.6)
  Seasonal allergy 8 (3.8) 8 (3.7) 15 (7.1)
  Eczema 12 (5.7) 10 (4.6) 8 (3.8)
  Elevated blood creatine phosphokinase 11 (5.2) 9 (4.1) 7 (3.3)
  Constipation 5 (2.4) 15 (6.9) 7 (3.3)
  Back pain 6 (2.9) 7 (3.2) 13 (6.1)
  Contact dermatitis 6 (2.9) 8 (3.7) 12 (5.7)
  Stomatitis 7 (3.3) 11 (5.0) 4 (1.9)
  Dental caries 11 (5.2) 6 (2.8) 4 (1.9)
*Serious AE.
†Serious drug-related AE: putamen haemorrhage.
‡Special interest AE: liver function test abnormal.
AE, adverse event; TEAE, treatment-emergent AE.
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as the clinical daily dose of vonoprazan for prevention of recur-
rent peptic ulcers during long-term NSAID therapy.
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